The Formulation and Evaluation of Topical Berberine-Hydrochloride Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Formulation and Evaluation of Topical Berberine-Hydrochloride Products
The authors sought to prepare a topical formulation of berberine hydrochloride for the effective and controlled management of inflammation and skin infections.


Pharmaceutical Technology
Volume 34, Issue 1, pp. 60-69

References

1. M. Ikram, Planta Med. 28 (4), 353–358 (1975).

2. K.C. Huang and W.M. Williams, "Antibacterial, Antiviral, and Antifungal Herbs," in The Pharmacology of Chinese Herbs, K.C. Huang, Ed. (CRC Press, New York, 2nd ed., 1999), pp. 381–383.

3. A.H. Amin, T.V. Subbaiah, and K.M. Abbasi, Can. J. Microbiol. 15 (9), 1067–1076 (1969).

4. K. Iwasa et al., J. Nat. Prod. 61 (9), 1150–1153 (1998).

5. D. Sun, S.N. Abraham, and E.H. Beachey, Antimicrob. Agents Chemother. 32 (8), 1274–1277 (1988).

6. J.G. Chung et al., Food. Chem. Toxicol. 37 (4), 319–326 (1999).

7. A.O. David and H.A. Anton, Topical Drug Delivery Formulations, A.O. David and H.A. Anton, Eds. (Marcel Dekker, New York, 1st ed., 1990), p. 1.

8. G.F. Webster, Clin. Cornerstone 4 (1), 33–38 (2001).

9. M.L. Freile et al., Fitoterapia 74 (7–8), 702–705 (2003).

10. C.L. Kuo, C.W. Chi, and T.Y. Liu, Cancer Lett. 203 (2), 127–137 (2004).

11. G. L. Darmstadt, J. G. Dinulos, and Z. Miller, Pediatrics 105 (2), 438–444 (2000).

12. R.C. Woolfall, Soap Perfum. Cosmet. 37 (2), 965–970 (1964).

13. O.A. Itiola, and N. Pilpel, J. Pharm. Pharmacol. 43 (3), 145–147 (1991).

14. O.A. Itiola, and N. Pilpel, Pharmazie 51 (4), 987–989 (1996).

15. A. Namdeo and N.K. Jain, J. Control. Release 82 (2–3), 223–236 (2002).

16. S. Mutalik and N. Udupa, J. Pharm. Sci. 93 (6), 1577–1594 (2004).

17. J.M. Harris and P.S.J. Spencer, J. Pharm. Pharmacol. 14 (6), 464–466 (1962).

18. P. Cornwell and B. Barry, J. Pharm. Pharmacol. 46 (4), 938–950 (1994).

19. A. Williams and B. Barry, Pharm. Res. 8 (1), 17–24 (1991).

20. Z. Kaidi and J. Singh, J. Control. Release 55 (2–3), 253–260 (1998).

21. J.H. Draize, G. Woodward, and H.O. Calvery, J. Pharmacol. Exp. Ther. 82 (3), 377–379 (1944).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here